NASDAQ:FENC Adherex Technologies (FENC) Stock Price, News & Analysis $10.60 -0.02 (-0.19%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$10.60 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainSEC FilingsShort Interest About Adherex Technologies Stock (NASDAQ:FENC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adherex Technologies alerts:Sign Up Key Stats Today's Range$10.51▼$10.8150-Day Range$9.57▼$12.7852-Week Range$5.65▼$13.25Volume105,064 shsAverage Volume222,016 shsMarket Capitalization$371.64 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview Adherex Technologies Inc. was a biotechnology company that focused on developing therapies for cancer treatment and treatment-related complications. The company is now known as Fennec Pharmaceuticals Inc. and trades on the Nasdaq under the symbol FENC. Fennec’s principal product is PEDMARK (sodium thiosulfate), a formulation designed to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children receiving cisplatin chemotherapy for localized, non-metastatic solid tumors. Cisplatin is widely used in cancer treatment but can cause permanent damage to hearing, particularly in pediatric patients. The company’s activities are centered on the development and commercialization of PEDMARK for pediatric oncology. Fennec serves the U.S. market and has pursued regulatory and commercial opportunities in other regions. The company’s current business represents the continuation of Adherex’s oncology-focused development efforts under the Fennec Pharmaceuticals name.AI Generated. May Contain Errors. Read More Adherex Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreFENC MarketRank™: Adherex Technologies scored higher than 84% of companies evaluated by MarketBeat, and ranked 79th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingAdherex Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdherex Technologies has a consensus price target of $17.00, representing about 60.4% upside from its current price of $10.60.Amount of Analyst CoverageAdherex Technologies has only been the subject of 4 research reports in the past 90 days.Read more about Adherex Technologies' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth246.43% Earnings GrowthEarnings for Adherex Technologies are expected to grow by 246.43% in the coming year, from $0.28 to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adherex Technologies is -81.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adherex Technologies is -81.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdherex Technologies has a P/B Ratio of 10.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adherex Technologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.74% of the float of Adherex Technologies has been sold short.Short Interest Ratio / Days to CoverAdherex Technologies has a short interest ratio ("days to cover") of 2.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adherex Technologies has recently increased by 4.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdherex Technologies does not currently pay a dividend.Dividend GrowthAdherex Technologies does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.05 News SentimentAdherex Technologies has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adherex Technologies this week, compared to 2 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adherex Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,660.00 in company stock.Percentage Held by Insiders10.73% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adherex Technologies' insider trading history. Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adherex Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FENC Stock News HeadlinesAdherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 23, 2026 | americanbankingnews.comFennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026September 17, 2026 | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 27 at 1:00 AM | Stansberry Research (Ad)Pierre Sargis Sayad Sells 12,000 Shares of Adherex Technologies (NASDAQ:FENC) StockSeptember 1, 2026 | insidertrades.comAdherex Technologies (NASDAQ:FENC) CFO Sells 75,000 SharesAugust 29, 2026 | insidertrades.comFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | globenewswire.comFennec Announces Results of Annual MeetingJune 10, 2026 | globenewswire.comAdherex Technologies' PEDMARK push targets larger AYA market after record quarterMay 23, 2026 | msn.comSee More Headlines FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Adherex Technologies' stock was trading at $7.70 at the beginning of the year. Since then, FENC stock has increased by 37.7% and is now trading at $10.60. How were Adherex Technologies' earnings last quarter? Adherex Technologies Inc. (NASDAQ:FENC) issued its quarterly earnings results on Thursday, August, 13th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $17.87 million for the quarter, compared to analysts' expectations of $16.21 million. Adherex Technologies had a negative trailing twelve-month return on equity of 5.71% and a negative net margin of 6.09%. Read the conference call transcript. How do I buy shares of Adherex Technologies? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adherex Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adherex Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/13/2026Today9/27/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FENC's financial health is in the Green zone, according to TradeSmith. FENC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:FENC CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490Employees35Year Founded1996Price Target and Rating Average Price Target for Adherex Technologies$17.00 High Price Target$18.00 Low Price Target$16.00 Potential Upside/Downside+60.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E Ratio37.86 P/E GrowthN/ANet Income-$9.74 million Net Margins-6.09% Pretax Margin-5.24% Return on Equity-5.71% Return on Assets-2.37% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio5.66 Sales & Book Value Annual Sales$44.64 million Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book10.19Miscellaneous Outstanding Shares35,060,000Free Float31,296,000Market Cap$371.64 million OptionableOptionable Beta1.10 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:FENC) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
